ECRI report identifies reasons weight loss drugs have been underutilised
ECRI, the largest non-profit patient safety organisation in the US, is calling on healthcare leaders to change their approach and fully...
ECRI report identifies reasons weight loss drugs have been underutilised
Triptan migraine drugs may be effective in treating obesity
FDA approves Phase II trial for obesity-treating drug pemvidutide
AstraZeneca and Regeneron to develop obesity treatments
EBWMP plus anti-obesity medications results in greater weight loss
FDA approves Novo Nordisk’s Wegovy (semaglutide 2.4 mg) for weight management